What The Study Did: An economic evaluation of 3.3 million drug insurance claims looked at whether implementing reference pricing was associated with physicians and patients adjusting to using the least expensive alternative within a drug class.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
Authors: James C. Robinson, Ph.D., University of California, Berkeley, School of Public Health, is the corresponding author.
(10.1001/jamanetworkopen.2019.20544)
Editor's Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.